Credit: PTI
The government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has increases prices of Anti-Rabies Immunoglobulin 300 IU/ml injection (1 ml) from ₹112.19 to ₹119.48, according to the news agency, ANI. Doctors give this injection in case of dog bites.
The regulator has also capped retail prices of 39 commonly used medicines used for hypertension, diabetes, heart disease and other therapies. The ceiling prices have been fixed under the provisions of the Drugs (Prices Control) Order, 2013.
According to the official document, NPPA has fixed the retail price of Calcium and Vitamin D3 Tablets at ₹8.93 per tablet inclusive of Goods & Services Tax (GST).
The revision is part of NPPA’s periodic review to ensure availability and affordability of critical care medicines. The price fixation and capping come amid the government’s continued push to make essential medicines more affordable and to check excessive pricing in the market.
Price revisions take effect immediately
NPPA has directed manufacturers and marketers to ensure that the revised prices are implemented immediately and that the new Maximum Retail Prices (MRP) are printed on packs along with the mandatory declaration.
Fixing prices of Calcium-Vitamin D3 tabs to help patients: Experts
Industry officials said to ANI that the inclusion of Calcium-Vitamin D3, widely prescribed for bone health and deficiency management, and Anti-Rabies Immunoglobulin, used in post-exposure prophylaxis, in the notified list will directly benefit patients and hospitals.
Decision to help households manage treatment costs
The capping of 39 medicines covering major lifestyle and cardiac drugs is also expected to bring relief to households managing long-term treatment costs. NPPA noted that the revised prices have been arrived at after considering market data and input costs.
Notifications have been issued by NPPA and will be applicable to manufacturers, importers and retailers across the country. Retailers have been asked to ensure that stocks with old MRP are cleared as per DPCO norms.
With these revisions, NPPA has now regulated prices of several key therapeutic categories in 2026, aiming to balance patient affordability with industry viability.
